Singapore finding leads to new Cervical Cancer treatments

The team from the NUS Cancer Science Institute of Singapore (CSI Singapore) found new molecular interactions involved in the development of tumors in cervical cancer.
They found that the human papilloma virus (HPV), which causes cervical cancer, interacts with a protein called EDD1 to destabilize a tumor suppressor protein, which stops the formation of tumors.
The three-year study also showed that an increase in a tumor suppressor protein called TIP60, found in the human body, could prevent the growth of cancer cells.
The protein acts as a "guardian of the cell" against cancerous growth, said Assistant Professor Sudhakar Jha, principal investigator at CSI Singapore, who was involved in the study.

The discovery is an exciting one, he says, as understanding the interactions is a critical first step towards coming up with treatments to target HPV-induced cancers.
Current treatment methods such as surgery and chemotherapy come with their limitations, he noted. "The problem with chemotherapy is that it kills not just the cancer cells but also other normal cells," said Prof Jha.
The roles of EDD1 and TIP60 had not been well explored in previous studies and this is the first to show how the protein EDD1 interacts with TIP60.
While still in its early stages, the finding could help develop treatments to either restore the tumour suppressor protein to normal levels or target the EDD1 protein. In patients with cervical cancer, the levels of TIP60 are 80 per cent lower than normal levels.